Loading clinical trials...
Loading clinical trials...
Study on the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen in CD19-targeting CAR-T Therapies
Conditions
Interventions
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
Locations
1
China
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
February 1, 2022
Primary Completion Date
August 1, 2024
Completion Date
December 30, 2025
Last Updated
July 17, 2025
NCT06395103
NCT07523555
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions